Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (eBook)

Michael W. Jann, Scott R. Penzak, Lawrence J. Cohen (Herausgeber)

eBook Download: PDF

2016 | 1st ed. 2016
XIV, 601 Seiten
Springer International Publishing (Verlag)
978-3-319-27883-4 (ISBN)

Infos

This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information forclinicians, students, researchers, and members of the pharmaceutical industry alike.

The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the central nervous system (CNS) compartment are presented on an individual basis and then applied to target populations with specific disease states. Methods and characteristics that inform the transfer of these drugs from the laboratory bench to use in patient care are discussed, including imaging techniques, genetics and physiological barriers, such as the blood-brain barrier. The second section describes the characteristics of specific agents,nominally arranged intodifferent therapeutic categories and with reference crossover use in different disease states. The pharmacologic characteristics of different drug formulations are explored in the context of their ability to improve patient adherence. The third section focuses on drug-drug interactions.Psychotropic medications from different categories are frequently prescribed together,or alongside medications used to treat comorbid conditions, and the information provided is directly relevant to the clinic, as a result.

The clinical application of pharmacokinetics and pharmacodynamics of CNS agents has made significant progress over the past 50 years and new information is reported by numerous publications in psychiatry, neurology, and pharmacology.Our understanding of the interrelationship between these medications, receptors, drug transporters, as well as techniques for measurement and monitoring their interactions,isfrequently updated. However, with information presented on a host of different platforms, and in different formats, obtaining the full picture can be difficult. This title aims to collate this information into a single source that can be easily interpreted and applied towards patient care by the clinical practitioner, and act as a reference for all others who have an interest in psychopharmacological agents.

Michael W. Jann, Pharm.D., FCP, FCCP is Professor and Chair for the Department of Pharmacotherapy at the University of North Texas System College of Pharmacy (UNTSCP) located at the UNT Health Sciences Center (UNTHSC). Professor Jann received his Doctor of Pharmacy degree from the University of Southern California and post-doctoral training in mental health pharmacy practice at the University of Tennessee Memphis College of Pharmacy. He has published over 230 peer-review articles, abstracts, and book chapters and served as a primary investigator for numerous clinical trials in psychopharmacology. Professor Jann serves on the editorial boards of six peer-review scientific journals including CNS Drugs, Molecular Diagnostics and Therapeutics, The Scientific World Journal - Pharmacology Section, The Consultant Pharmacist, Journal of Clinical Pharmacology, and Journal of Pharmacy Practice.

Scott R. Penzak, Pharm.D., FCP, is Professor and Vice Chair for the Department of Pharmacotherapy at the University of North Texas System College of Pharmacy (UNTSCP) located at the UNT Health Sciences Center (UNTHSC). Professor Penzak received his Doctor of Pharmacy degree from Wayne State University and completed his post-doctoral training in infectious diseases at the University of Arkansas for Medical Science (UAMS). Prior to UNTSCP, he was the Director of the Clinical Pharmacokinetics Laboratory at the NIH.  He has published over 150 peer-review articles, abstracts, and book chapters, and served as a principal investigator on numerous pharmacokinetic and pharmacogeneticstudies. Professor Penzak serves on the editorial boards of three peer-review scientific journals including Journal of Clinical Pharmacology, Pharmacotherapy, and the International Journal of Pharmacokinetics.

Lawrence J. Cohen, PharmD, BCPP, FASHP, FCCP, FCP, FNAP is currently Professor of Pharmacotherapy at the University of North Texas System College of Pharmacy. Examples of Professor Cohen's previous service include, Global Director of CNS Research for Kendle International, Director of the Office of Clinical Trials for University of Cincinnati, and Director of Pharmaceutical Services for the Oklahoma Department of Mental Health and Substance Abuse Services. Professor Cohen received his Doctor of Pharmacy degree and post-doctoral training in psychiatric pharmacy from University of Southern California School of Pharmacy. Professor Cohen has been a Board Certified Psychiatry Pharmacist since the specialty was recognized. His relevant service on Editorial Boards include Current Psychiatry, Innovations in Clinical Neuroscience, Primary Care Companion of the Journal of Clinical Psychiatry, Drug Benefit Trends, Journal of the American Medical Directors Association, CNS News and Pharmacy Practice News.

Inhalt

Section 1. General Pharmacokinetic and Pharmacodynamic Principles of
Psychopharmacological Agents.- 1. Pharmacokinetic Properties.- 2. Pharmacodynamic
Properties.- 3. PET Scan and Other Biomarkers.- 4. Population
Pharmacokinetics.- 5. Drug Transporters (esp. Blood Brain Barrier).- 6. Pharmacogenomics.-
Section 2. Clinical Pharmacokinetics and Pharmacodynamics of
Psychopharmacological Drug Classes.- 7. Antipsychotics – oral typical agents,
oral atypical agents, and long-acting injectable (LAI) antipsychotics.- 8. Mood
Stabilizers.- 9. Antidepressants – tricyclics, selective serotonergic reuptake
inhibitors, serotonergic noradrenergic reuptake inhibitors, monoamine oxidase
inhibitors, and other antidepressants.- 10. Benzodiazepines and Other Sedative
Hypnotics/Anxiolytics.- 11. Opioid Analgesics.- 12. Stimulants and Other
Non-Stimulants for ADHD.- 13. Cholinesterase Inhibitors and Other Antidementa
Agents.- 14. Anti-Addiction Agents.- 15. Anesthetics.- Section 3. Clinically
Significant Drug Interactions With Psychopharmacological Agents.- 16.
Antipsychotics.- 17. Mood Stabilizers.- 18. Antidepressants.- 19.
Benzodiazepines and Other Sedative Hypnotics/Anxiolytics.- 20. Opioid
Analgesics.- 21. Stimulants and Other Non-Stimulants for ADHD.- 22. Cholinesterase
Inhibitors and Other Antidementa Agents.- 23. Anti-Addiction Agents.- 24.
Anesthetics.

Produkt-Details

• Erscheint lt. Verlag: 2.3.2016
• Zusatzinfo: XIV, 601 p. 100 illus., 50 illus. in color.
• Verlagsort: Cham
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete
• Themenwelt: Medizin / Pharmazie ► Pharmazie
• Schlagworte: Acetylaldehyde Hydrogenase • Atypical • Candidate Gene • cell membrane • central nervous system • CYP2C19 Enzyme • Emax Model • Grapefruit Juice • Immediate-Release Formulation • Immunosuppressants • Inhibitor • Kappa Opiate Receptor • Modeling Analysis • muscle relaxant • N-Methyl-D-Aspartate (NMDA) Receptor • Non-Steroid Anti-inflammatory Drugs (NSAIDs) • prophylaxis • Protein Binding Interactions • Radiotracer • Receptor systems
• ISBN-10: 3-319-27883-5 / 3319278835
• ISBN-13: 978-3-319-27883-4 / 9783319278834